N/A N=15 Radiosurgery and Avastin for Recurrent Malignant Gliomas
Malignant Glioma
Primary: Central Nervous System (CNS) Toxicity — 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=34 Monthly SOM230C for Recurrent or Progressive Meningioma
Meningioma
Primary: 6 Month Progression Free Survival — 11; 44 percentage of patients
Phase 2 N=17 Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases
Brain Tumor · Brain Metastases
Primary: Affects of Response Rate of Chemotherapy With Intra-arterial Carboplatin and Oral Temozolomide — 42.8 percentage of patients with response
Phase 2 N=121 Lerapolturev in Recurrent Malignant Glioma
Malignant Glioma
Primary: Number of Participants With Objective Radiographic Response — 5; 2 Participants
Phase 1 N=16 Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD) — 0; 0; 0; 1 Participants
Phase 2 N=88 Bevacizumab for Recurrent Malignant Glioma
Recurrent High-Grade Gliomas · Malignant Gliomas
Primary: Percentage of Participants With Progression Free Survival at 6 Months. — 20.9; 29 Percentage of participants
Phase 2 N=219 Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma
Central Nervous System Lymphoma
Primary: Complete Remission Rate After Primary Chemotherapy — 23; 30; 49 Percentage of participants
Phase 2 N=151 A Study in Subjects With Recurrent Malignant Glioma
Glioma
Primary: Progression Free Survival (PFS) Rate at Month 6 — 11.0; 21.2; 8.0; 7.6 Percentage of participants
Phase 2 N=26 Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor
Medulloblastoma · Neuroectodermal Tumor
Primary: 12 Month Progression-free Survival (PFS-12) — 215; 69 Days — p=0.927
Phase 2 N=59 Ph II Bevacizumab + Etoposide for Pts w Recurrent MG
Glioblastoma · Gliosarcoma
Primary: 6 Month Progression-Free Survival (PFS) — 41; 44 percentage of participants
Phase 2 N=81 Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
Glioblastoma Multiforme
Primary: Percentage of Subjects With Progression-free Survival — 7.5; 15.0 percentage of subjects
Phase 2 N=47 Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Glioblastoma · Grade IV Astrocytoma · Glioblastoma Multiforme
Primary: Overall Survival (OS) — 10.2; 11.64 months
Phase 2 N=22 Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma
Recurrent Glioma
Primary: Number of Participants With Adverse Events — 0; 1; 3; 3 Participants
Phase 2 N=31 Sunitinib in Treating Patients With Recurrent Malignant Gliomas
Adult Anaplastic Astrocytoma · Adult Diffuse Astrocytoma · Adult Giant Cell Glioblastoma
Primary: Progression-free Survival at 6 Months (Stratum 1) — 1 patients
Phase 1 N=26 Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors
Central Nervous System Tumors
Primary: Measurement of Number of Adverse Events — 4; 6; 3; 5 Adverse events
Phase 1 N=3 Topotecan by Intracerebral Clysis for Recurrent Primary Malignant Brain Tumors
Brain Neoplasms, Primary Malignant
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 0 Participants
Phase 3 N=35 Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy
Recurrent or Progressive Glioblastoma
Primary: Local Tumor Control — 14; 4 Participants
Phase 2 N=23 Imatinib Mesylate in Treating Patients With Recurrent Meningioma
Adult Grade I Meningioma · Adult Grade II Meningioma · Adult Grade III Meningioma
Primary: 6 Months - Progression-free Survival According to Response Evaluation Using Macdonald Criteria — 29.4 percentage of participants
Phase 1 N=61 PVSRIPO for Recurrent Glioblastoma (GBM)
GBM · Glioblastoma · Glioma
Primary: Maximum Tolerated Dose (MTD) — 10,000,000,000 50% Tissue Culture Infectious Dose
Phase 2 N=35 Carboplatin and Bevacizumab for Recurrent Ependymoma
Ependymoma · Anaplastic Ependymoma
Primary: Percentage of Participants That Have Progressive Free Survival (PFS) After 1 Year — 76.4 Percentage of participants
Phase 2 N=62 Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma
High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
Primary: ORR — 0; 0; 0; 0 percentage of patients
Phase 2 N=60 Temozolomide in Treating Patients With Recurrent High-Grade Glioma
Recurrent Central Nervous System Neoplasm
Primary: 6 Month Progression-free Survival — 10; 50 percentage of patients
Phase 3 N=356 Radiation Therapy in Preventing Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer
Lung Cancer
Primary: Overall Survival — 28.5; 25.3 months — p=0.2853
Phase 2 N=90 Trabectedin for Recurrent Grade II/III Meningioma
Recurrent High Grade Meningioma
Primary: Progression Free Survival (PFS) — 4.17; 2.43 Months — p=0.204
Phase 2 N=33 Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
Gliomas
Primary: Overall Response Rate — 9 percent
Phase 2 N=51 Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Brain Metastasis · Bladder Cancer · Breast Cancer
Primary: Local Control — 13; 23; 2; 1 participants
Phase 1 N=13 INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
Glioblastoma Multiforme · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Number of Patients Who Experienced Dose-limiting Toxicities (DLTs) — 3 Participants
Phase 2 N=43 Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors
Glioma
Primary: Response, Defined as Stable Disease or Objective (Partial or Complete) Response. — 0; 0; 0; 0 Participants
Phase 2 N=15 Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma
Central Nervous System Tumor, Pediatric · Neuroblastoma
Primary: Therapy Completion Rate — .40 proportion of participants
Phase 2 N=91 Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Chemotherapeutic Agent Toxicity · Cognitive/Functional Effects · Lymphoma
Primary: Progression-free Survival — 2.1; NA years — p=0.015